Landry Robert E
SEC CIK 1585160 · EDGAR
BoughtSold
Most active insiders at CYTK, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Blum Robert I | Pres, CEO, Dir | — | $17.08M |
| 2 | Callos Andrew | EVP, Chief Commercial Off | — | $16.02M |
| 3 | Lee Sung | EVP, CFO | — | $5.70M |
| 4 | Malik Fady Ibraham | EVP Research, Development | — | $4.65M |
| 5 | Kaye Edward M. MD | Dir | — | $3.21M |
| 6 | HENDERSON JOHN T | Dir | — | $2.08M |
| 7 | WIERENGA WENDELL | Dir | — | $1.88M |
| 8 | PARSHALL B LYNNE | Dir | — | $1.36M |
| 9 | Landry Robert E | Dir | — | $146.8K |
| 10 | Harrington Robert Arthur | Dir | — | $143.6K |
Transactions 72
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-15 17:23 | 2026-09-15 | CYTK | CYTOKINETICS INC | Landry Robert E | Dir | S - Sale | $72.13 | -1,000 | 8,184 | -11% | -$72.1K |
| T | 2026-09-11 19:12 | 2026-09-11 | CYTK | CYTOKINETICS INC | Landry Robert E | Dir | S - Sale | $74.66 | -1,000 | 9,184 | -10% | -$74.7K |
| D | 2026-05-27 19:09 | 2026-05-27 | CYTK | CYTOKINETICS INC | Landry Robert E | Dir | A - Grant | $0.00 | +2,851 | 10.2K | +39% | $0 |
| D | 2025-05-14 | 2025-05-14 | CYTK | CYTOKINETICS INC | Landry Robert E | Dir | A - Grant | $0.00 | +7,333 | 7,333 | New | $0 |
| D | 2024-02-06 | 2024-02-02 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $378.98 | +400 | 24.0K | +2% | +$151.6K |
| D | 2024-02-06 | 2024-02-02 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $956.65 | -281 | 23.7K | -1% | -$268.8K |
| D | 2024-02-02 | 2024-01-31 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $378.98 | +400 | 23.9K | +2% | +$151.6K |
| D | 2024-02-02 | 2024-01-31 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $953.42 | -282 | 23.6K | -1% | -$268.9K |
| DM | 2024-01-25 | 2024-01-23+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $949.36 | -1,128 | 23.5K | -5% | -$1.07M |
| DM | 2024-01-25 | 2024-01-23+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $378.98 | +1,600 | 24.1K | +7% | +$606.4K |
| D | 2024-01-18 | 2024-01-17 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $932.34 | -354 | 23.0K | -2% | -$330.0K |
| D | 2024-01-18 | 2024-01-17 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $378.98 | +500 | 23.3K | +2% | +$189.5K |
| D | 2024-01-17 | 2024-01-12 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $378.98 | +800 | 23.4K | +4% | +$303.2K |
| D | 2024-01-17 | 2024-01-12 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $928.18 | -568 | 22.8K | -2% | -$527.2K |
| D | 2024-01-08 | 2024-01-04 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $917.05 | -342 | 22.6K | -1% | -$313.6K |
| D | 2024-01-08 | 2024-01-04 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $378.98 | +500 | 22.9K | +2% | +$189.5K |
| DM | 2024-01-04 | 2024-01-02+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $378.98 | +1,750 | 23.1K | +8% | +$663.2K |
| DM | 2024-01-04 | 2024-01-02+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $903.20 | -1,109 | 22.0K | -5% | -$1.00M |
| DM | 2023-12-29 | 2023-12-27+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $378.98 | +1,600 | 22.4K | +8% | +$606.4K |
| DM | 2023-12-29 | 2023-12-27+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $878.93 | -1,154 | 21.8K | -5% | -$1.01M |
| DM | 2023-12-14 | 2023-12-12+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $858.18 | -7,104 | 21.1K | -25% | -$6.10M |
| D | 2023-12-14 | 2023-12-13 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $378.98 | +1,000 | 22.1K | +5% | +$379.0K |
| M | 2023-12-12 | 2023-12-08+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $844.02 | -4,234 | 30.0K | -12% | -$3.57M |
| 2023-08-25 | 2023-08-23 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | S - Sale | $844.00 | -223 | 31.7K | -0.7% | -$188.2K | |
| DM | 2023-03-29 | 2023-03-27+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | S - Sale+OE | $823.20 | -1,190 | 32.9K | -3% | -$979.6K |
| DM | 2023-03-29 | 2023-03-27 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $379.60 | +3,800 | 35.3K | +12% | +$1.44M |
| DM | 2023-03-29 | 2023-03-27 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $825.17 | -2,793 | 33.1K | -8% | -$2.30M |
| DM | 2023-02-07 | 2023-02-03+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | S - Sale+OE | $776.80 | -1,491 | 32.7K | -4% | -$1.16M |
| D | 2023-02-07 | 2023-02-03 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $774.29 | -2,248 | 32.9K | -6% | -$1.74M |
| D | 2023-02-07 | 2023-02-03 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $381.92 | +3,000 | 35.1K | +9% | +$1.15M |
| D | 2022-12-20 | 2022-12-16 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | A - Grant | $0.00 | +3,853 | 32.8K | +13% | $0 |
| D | 2022-12-12 | 2022-12-08 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $381.92 | +3,000 | 31.7K | +10% | +$1.15M |
| DM | 2022-12-12 | 2022-12-08+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $765.81 | -2,753 | 29.5K | -9% | -$2.11M |
| D | 2022-12-02 | 2022-12-01 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $760.35 | -1,890 | 29.4K | -6% | -$1.44M |
| D | 2022-12-02 | 2022-12-01 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $381.92 | +2,500 | 31.2K | +9% | +$954.8K |
| DM | 2022-12-02 | 2022-12-02 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | S - Sale+OE | $756.66 | -610 | 28.8K | -2% | -$461.6K |
| DM | 2022-11-02 | 2022-11-01 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | S - Sale+OE | $758.06 | -482 | 28.8K | -2% | -$365.4K |
| D | 2022-11-02 | 2022-10-31 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $381.92 | +2,000 | 30.7K | +7% | +$763.8K |
| D | 2022-11-02 | 2022-10-31 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $751.24 | -1,518 | 29.2K | -5% | -$1.14M |
| D | 2022-10-18 | 2022-10-14 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $381.92 | +1,500 | 30.2K | +5% | +$572.9K |
| D | 2022-10-18 | 2022-10-17 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | S - Sale+OE | $739.50 | -358 | 28.7K | -1% | -$264.7K |
| D | 2022-10-18 | 2022-10-14 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $743.78 | -1,142 | 29.1K | -4% | -$849.4K |
| DM | 2022-04-11 | 2022-04-07+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $388.46 | +9,500 | 32.2K | +42% | +$3.69M |
| DM | 2022-04-11 | 2022-04-07+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $732.98 | -7,313 | 30.6K | -19% | -$5.36M |
| DM | 2022-04-11 | 2022-04-08+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | S - Sale+OE | $734.61 | -2,187 | 28.7K | -7% | -$1.61M |
| D | 2022-04-01 | 2022-03-31 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $399.66 | +1,500 | 30.2K | +5% | +$599.5K |
| DM | 2022-04-01 | 2022-04-01 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | S - Sale+OE | $695.81 | -316 | 28.8K | -1% | -$219.9K |
| D | 2022-04-01 | 2022-03-31 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $700.99 | -1,184 | 29.1K | -4% | -$830.0K |
| DM | 2022-03-30 | 2022-03-28 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $685.26 | -11.8K | 28.9K | -29% | -$8.10M |
| DM | 2022-03-30 | 2022-03-29 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | S - Sale+OE | $687.90 | -2,683 | 30.4K | -8% | -$1.85M |
| DM | 2022-03-30 | 2022-03-28 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $426.56 | +14.5K | 30.0K | +94% | +$6.19M |
| D | 2022-03-23 | 2022-03-21 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $691.31 | -312 | 28.7K | -1% | -$215.7K |
| D | 2022-03-23 | 2022-03-21 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | S - Sale+OE | $693.00 | -300 | 28.7K | -1% | -$207.9K |
| D | 2022-03-23 | 2022-03-21 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $381.92 | +400 | 29.1K | +1% | +$152.8K |
| D | 2022-03-18 | 2022-03-17 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $682.50 | -286 | 29.0K | -1.0% | -$195.2K |
| DM | 2022-03-18 | 2022-03-16+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | S - Sale+OE | $678.95 | -383 | 28.9K | -1% | -$260.0K |
| D | 2022-03-18 | 2022-03-17 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $381.92 | +365 | 29.2K | +1% | +$139.4K |
| DM | 2021-12-14 | 2021-12-10+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $664.34 | -2,081 | 29.4K | -7% | -$1.38M |
| D | 2021-12-14 | 2021-12-13 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | S - Sale+OE | $662.50 | -116 | 29.3K | -0.4% | -$76.8K |
| D | 2021-12-14 | 2021-12-10 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $555.67 | +1,500 | 31.5K | +5% | +$833.5K |
| DM | 2021-12-10 | 2021-12-10 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | S - Sale+OE | $666.42 | -781 | 30.7K | -2% | -$520.5K |
| D | 2021-12-10 | 2021-12-08 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | A - Grant | $0.00 | +3,971 | 30.0K | +15% | $0 |
| D | 2021-12-10 | 2021-12-09 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $399.66 | +4,250 | 34.2K | +14% | +$1.70M |
| D | 2021-12-10 | 2021-12-09 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $657.11 | -3,469 | 30.7K | -10% | -$2.28M |
| D | 2021-11-18 | 2021-11-17 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | S - Sale+OE | $645.08 | -681 | 26.0K | -3% | -$439.3K |
| D | 2021-11-18 | 2021-11-16 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $651.97 | -3,069 | 26.7K | -10% | -$2.00M |
| D | 2021-11-18 | 2021-11-16 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $399.66 | +3,750 | 29.7K | +14% | +$1.50M |
| D | 2021-09-01 | 2021-08-31 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $555.67 | +1,000 | 26.9K | +4% | +$555.7K |
| D | 2021-09-01 | 2021-08-31 | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $675.03 | -917 | 26.0K | -3% | -$619.0K |
| DM | 2021-08-10 | 2021-08-09+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | S - Sale+OE | $614.30 | -901 | 25.9K | -3% | -$553.5K |
| DM | 2021-08-10 | 2021-08-06+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | F - Tax | $613.62 | -4,099 | 26.3K | -13% | -$2.52M |
| DM | 2021-08-10 | 2021-08-06+ | REGN | Regeneron Pharmaceuticals | Landry Robert E | EVP Fin CFO | M - OptEx | $381.92 | +5,000 | 27.9K | +22% | +$1.91M |
Purchase Sale Sale after option exercise All abbreviations